Drug intelligence / Profile preview

Tris-CAR-T cells

Development stage: Unknown
Lead developer: Tasly Pharmaceutical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intrathecal

Overview

**Tris-CAR-T cells** are an autologous, locoregionally administered, tandem bispecific CAR-T-cell therapy for recurrent glioblastoma. Patient-derived T cells are lentivirally engineered to recognize the glioma stem cell-associated antigens **CD44** and **CD133**, with a truncated interleukin-7 receptor alpha intracellular-domain armor intended to support CAR-T-cell persistence and function. The product is being evaluated through intraventricular or intracavitary administration via an Ommaya reservoir in a Phase 1 study of recurrent glioblastoma.

Other names: Tanζ-T28-Δ7R CAR-T cellsTris-CAR-TTris-CAR-T cells

Targets

CD133 (CD133 antigen)CD44 (CD44 antigen)

Beyond the preview

Go deeper on Tris-CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tris-CAR-T cells.

Explore the full profile